Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111169 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAAL3MBTL1CYP2C9HTT | |
| SCHEMBL11205882 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAAL3MBTL1CYP2C9HTT | |
| SCHEMBL8995484 | 0.89 | GAA (0.44) | ALDH1A1GAAL3MBTL1CYP2C9HTT | |
| SCHEMBL13198957 | 0.87 | ALDH1A1 (0.57) | ALDH1A1GAAL3MBTL1CYP2C9HTT | |
| SCHEMBL8971898 | 0.87 | CTSD (0.48) | ALDH1A1GAAL3MBTL1CYP2C9HTT | |
| SCHEMBL112747 | 0.86 | PPID (0.53) | ALDH1A1GAAL3MBTL1CYP2C9FNTA | |
| SCHEMBL112746 | 0.86 | PPID (0.53) | ALDH1A1GAAL3MBTL1CYP2C9FNTA | |
| SCHEMBL7599923 | 0.85 | ALDH1A1 (0.56) | ALDH1A1GAAL3MBTL1CYP2C9HTT | |
| SCHEMBL28501721 | 0.85 | ALDH1A1 (0.56) | ALDH1A1GAAL3MBTL1CYP2C9HTT | |
| SCHEMBL12064029 | 0.84 | SMN1; SMN2 (0.45) | ALDH1A1GAAL3MBTL1CYP2C9FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109628544-B | Application of lipase in resolution of N-acetyl-DL-methionine methyl ester | 浙江工业大学 | 2022-03-15 | — | — | CN | claimed |
| EP-3684412-A1 | METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2020-07-29 | — | — | EP | claimed |
| CN-111372610-A | Method for preventing oxidation of methionine in immunoconjugates | 伊缪诺金公司 | 2020-07-03 | — | — | CN | claimed |
| CN-109628544-A | A kind of lipase is splitting the application in N- acetyl-DL- methionine methyl ester | 浙江工业大学 | 2019-04-16 | — | — | CN | claimed |
| WO-2019060707-A1 | METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES | IMMUNOGEN, INC. (US) | 2019-03-28 | — | — | WO | claimed |
| CN-102802605-A | Stable lipid formulations of apoptosis promoters | ABBOTT LAB | 2012-11-28 | — | — | CN | claimed |
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| US-4367344-A | CYCLIZATION, 2-CYCLOAMINO-4-METHYLTHIOBUTANOIC ESTER | BAYER AKTIENGESELLSCHAFT (DE) | 1983-01-04 | — | — | US | claimed |
| EP-0025141-B1 | PROCESS FOR THE PRODUCTION OF 1-AMINO-CYCLOPROPANE-CARBOXYLIC ACID AND ITS DERIVATIVES | BAYER AG (DE) | 1982-05-12 | — | — | EP | claimed |
| EP-0025141-A1 | Process for the production of 1-amino-cyclopropane-carboxylic acid and its derivatives | BAYER AG (DE) | 1981-03-18 | — | — | EP | claimed |
| US-3963573-A | Process for producing N-acyl-L-methionine | THE PROCTER & GAMBLE COMPANY (US) | 1976-06-15 | — | — | US | claimed |
| US-3952115-A | Fortification of foodstuffs with N-acyl derivatives of sulfur-containing L-amino acid esters | THE PROCTER & GAMBLE COMPANY (US) | 1976-04-20 | — | — | US | claimed |
| US-20240350652-A1 | METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES | IMMUNOGEN INC (US) | 2024-10-24 | — | — | US | disclosed |
| CN-118724774-A | N-O bond guanidine compound, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2024-10-01 | — | — | CN | disclosed |
| US-20240316223-A1 | Oxidative Cyclization Reagents for Chemoselective Tryptophan Bioconjugation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-26 | — | — | US | disclosed |
| WO-1980002421-A1 | PROCESS FOR PRODUCING N-ACYL-D-PHENYLALANINE ESTER | ETHYL CORP (US) | 1980-11-13 | — | — | WO | disclosed |
| US-3963573-A | Process for producing N-acyl-L-methionine | THE PROCTER & GAMBLE COMPANY (US) | 1976-06-15 | — | — | US | disclosed |
| US-3952115-A | Fortification of foodstuffs with N-acyl derivatives of sulfur-containing L-amino acid esters | THE PROCTER & GAMBLE COMPANY (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316223-A1 | Oxidative Cyclization Reagents for Chemoselective Tryptophan Bioconjugation | TDO2, TPH1, TPH2 | ALDH1A1 684/4885GAA 3372/4885L3MBTL1 3303/4885 |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | ALDH1A1 3985/4885GAA 3697/4885L3MBTL1 375/4885 |
| US-20240350652-A1 | METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES | BHMT2, MGMT, MTR | ALDH1A1 211/4885GAA 2030/4885L3MBTL1 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.